AstraZeneca PLC
XHAM:ZEG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
AstraZeneca PLC (ZEG) under the Base Case is EUR per share.
Compared with the current market price of 166.1 EUR, the stock appears .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Intrinsic value next to the price over the past 5 years, and what happened after valuations like today’s.
Create a free account · No card needed
Fundamental Analysis
What AstraZeneca Does
AstraZeneca is a global pharmaceutical company that discovers, develops, and sells prescription medicines. Its drugs treat major illnesses such as cancer, heart and kidney disease, respiratory conditions, and rare diseases. The company works with doctors, hospitals, and health systems, and it earns money mainly by selling patented medicines and, in some cases, by licensing or partnering on drug programs.
- Headquarters
- United Kingdom UK
- Employees
- 96 100
- IPO date
- Sep 21, 2007
AstraZeneca has a wide economic moat
Patents and exclusive rights to sell approved medicines prevent rivals from offering cheaper copies of AstraZeneca’s protected treatments. Its range of protected drugs and continuing development of new medicines spread that protection across several diseases rather than relying on a single product.
Read the full moat analysis
Revenue & Expenses Breakdown
AstraZeneca PLC
Earnings Waterfall
AstraZeneca PLC
What is the Intrinsic Value of one ZEG stock?
The intrinsic value for AstraZeneca PLC (ZEG) under the Base Case is EUR.
Is ZEG stock undervalued or overvalued?
Compared with the current market price of 166.1 EUR, the stock appears .
